TABLE 1.
Baseline characteristics and demographics of patients who underwent percutaneous endoscopic gastrostomy tube insertion
| Variables | Nonhead and neck cancer | Head and neck cancer | Total | P |
|---|---|---|---|---|
| n = 187 (%) | n = 129 (%) | n = 316 (%) | ||
| Male | 113 (60.4) | 106 (82.2) | 219 (69.3) | <.001 |
| Age (years), mean ± SD | 67.33 ± 14.71 | 59.75 ± 11.00 | 64.24 ± 13.81 | <.001 |
| Underlying disease | ||||
| Neurologic diseases | 128 (68.4) | 8 (6.2) | 166 (52.5) | .000 |
| Solid cancer | 15 (8.0) | 129 (100) | 144 (52.5) | .000 |
| Diabetes mellitus | 50 (26.7) | 22 (17.1) | 72 (22.8) | .044 |
| Heart diseases | 24 (12.8) | 5 (3.9) | 29 (9.2) | .007 |
| Chronic lung diseases | 10 (5.3) | 3 (2.3) | 13 (4.1) | .184 |
| Chronic renal diseases | 10 (5.3) | 3 (2.3) | 13 (4.1) | .184 |
| Chronic liver diseases | 4 (2.1) | 1 (0.8) | 5 (1.5) | .652 |
| PEG site infection | 25 (13.4) | 42 (32.6) | 67 (21.2) | <.001 |
| Early infection | 8 (32.0) | 11 (26.2) | 19 (28.4) | .610 |
| Late infection | 17 (68.0) | 31 (73.8) | 48 (71.6) | |
| Prophylactic antibiotics | 180 (96.3) | 124 (96.1) | 304 (96.2) | 1.000 |
| Prior antibiotic therapy | 89 (47.6) | 99 (75.2) | 188 (59.5) | <.001 |
| Penicillin | 47 (25.1) | 43 (33.3) | 90 (28.5) | .128 |
| Cephalosporin | 14 (7.5) | 28 (21.7) | 42 (13.3) | <.001 |
| Fluoroquinolone | 22 (11.8) | 18 (14.0) | 40 (12.7) | .565 |
| Carbapenems a | 16 (8.6) | 14 (10.9) | 30 (9.5) | .494 |
| Glycopeptide | 16 (8.6) | 20 (15.5) | 36 (11.4) | .056 |
Note: Values are presented as no. (%) unless otherwise indicated.
Abbreviations: PEG, percutaneous endoscopic gastrostomy; SD, standard deviation.
a
Includes imipenem and meropenem.